Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript

Friedrich Finckenstein: Yes, a really good question and I love getting a question on the endometrial program. Thank you. So as you know, what we are seeing happening right now with the [indiscernible] is moving from a second-line treatment setting into frontline, the data on what’s being used and the efficacy after use of is really not available. So I think probably the best benchmark of a starting point of where you can — what you can look at as a potential benchmark would be data that have been used when Pembrolizumab was brought into the second line setting. There the control arm of study Keynote-775 was investigators choice monotherapy. And those showed an ORR of about 15% median duration of response of 5.7 months in patients with MMR proficient tumors.

The results in the MMR patients were a little lower with ORR 12% and median DOR of 4.1 months. So I think that’s probably where you can start given that we would be exploring populations that have seen both chemo, frontline chemo, which was the prior therapy for patients in this study in Keynote-775, but also either concomitant or sequential checkpoint inhibitor therapy, I think it’s fair to say that we would be — we would shoot to beat an ORR of about 10% to 15%.

Operator: That concludes the question-and-answer session. At this time, I would like to turn the call back to Fred Vogt for closing remarks.

Frederick Vogt: Thank you again for joining the Iovance Biotherapeutics third quarter 2023 financial results and corporate update conference call. We’ve had a productive year-to-date with a priority review of the BLA, the close of the Proleukin transaction, important milestones to lung cancer and delivering on our key regulatory commercial manufacturing and pipeline activities. I’m grateful for the patients, physicians and regulators as well as for our employees and cross-functional teams who have collaborated on our BLA submission while advancing our mission to be the global leader in TIL therapy. I’d also like to thank our shareholders and covering analysts for their support. Please feel free to reach out to our Investor Relations team for follow up. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.